Francisco Sanchez-Vega

TL;DR: The experience with next-generation sequencing is reported to characterize the prevalence and genomic landscape of actionable genomic alterations in renal cell carcinoma (RCC) and to describe the distribution of these alterations in the literature.

TL;DR: In this paper, the emerging role of NGS technologies to better understand tumor biology in patients with non-small cell lung cancer who are undergoing surgery with curative intent is discussed, where tumor heterogeneity, the underlying tumor genomics associated with lung adenocarcinoma subtypes, the prediction of recurrence after complete surgical resection, the use of plasma circulating tumor DNA for detection of early cancers and monitoring for minimal residual disease, the differentiation of separate primaries from intrapulmonary metastases, and the used NGS to guide induction and adjuvant therapies.

TL;DR: The entire cohort of 412 tumors from the TCGA project in chemotherapy-naive, muscle-invasive urothelial bladder cancer is reported on, with a high overall somatic mutation rate and APOBEC mutagenesis explained 70% of the mutation burden and was associated with survival.

TL;DR: In this article, the authors used a multigene next-generation sequencing panel to identify genomic differences in colorectal cancer patients in Nigeria compared to those from TCGA and MSKCC cohorts.

TL;DR: Somatic tumor mutations of STK11, KRAS, CTNNB1, KEAP1, CDKN2B and MET were associated with an increased risk of VTE in solid tumor patients, and the presence of clonal hematopoiesis was not associated with a increased VTE rate.